Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 49

  1. Cat.No. Product Name Information/Activity
  2. BCC4219 Aniracetam Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR. Aniracetam chemical structure
  3. BCC6974 IDRA 21 22503-72-6 IDRA 21 chemical structure
  4. BCC5787 pep2-AVKI 1315378-69-8 pep2-AVKI chemical structure
  5. BCC5786 pep2-EVKI 1315378-67-6 pep2-EVKI chemical structure
  6. BCC5782 pep2m 243843-42-7 pep2m chemical structure
  7. BCC5784 pep2-SVKI 328944-75-8 pep2-SVKI chemical structure
  8. BCC7135 IEM 1460 121034-89-7 IEM 1460 chemical structure
  9. BCC5049 IEM 1754 dihydrobroMide IEM 1754 2HBr is a selective AMPA/kainate receptor blockers for GluR1 and GluR3 with IC50 of 6 μM. IEM 1754 dihydrobroMide chemical structure
  10. BCC6909 1-BCP 1-BCP (Piperonylic acid piperidide) is a centrally active drug that modulates AMPA receptor gated currents. 1-BCP is a memory-enhancing agent. 1-BCP chemical structure
  11. BCC6868 Diazoxide Diazoxide (Sch-6783) is an ATP-sensitive potassium channel activator, has the potential for hyperinsulinism treatment. Diazoxide chemical structure

Items 481 to 490 of 709 total